Literature DB >> 32191764

Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China.

Mingli Yuan1, Wen Yin1, Zhaowu Tao1, Weijun Tan1, Yi Hu1.   

Abstract

Radiologic characteristics of 2019 novel coronavirus (2019-nCoV) infected pneumonia (NCIP) which had not been fully understood are especially important for diagnosing and predicting prognosis. We retrospective studied 27 consecutive patients who were confirmed NCIP, the clinical characteristics and CT image findings were collected, and the association of radiologic findings with mortality of patients was evaluated. 27 patients included 12 men and 15 women, with median age of 60 years (IQR 47-69). 17 patients discharged in recovered condition and 10 patients died in hospital. The median age of mortality group was higher compared to survival group (68 (IQR 63-73) vs 55 (IQR 35-60), P = 0.003). The comorbidity rate in mortality group was significantly higher than in survival group (80% vs 29%, P = 0.018). The predominant CT characteristics consisted of ground glass opacity (67%), bilateral sides involved (86%), both peripheral and central distribution (74%), and lower zone involvement (96%). The median CT score of mortality group was higher compared to survival group (30 (IQR 7-13) vs 12 (IQR 11-43), P = 0.021), with more frequency of consolidation (40% vs 6%, P = 0.047) and air bronchogram (60% vs 12%, P = 0.025). An optimal cutoff value of a CT score of 24.5 had a sensitivity of 85.6% and a specificity of 84.5% for the prediction of mortality. 2019-nCoV was more likely to infect elderly people with chronic comorbidities. CT findings of NCIP were featured by predominant ground glass opacities mixed with consolidations, mainly peripheral or combined peripheral and central distributions, bilateral and lower lung zones being mostly involved. A simple CT scoring method was capable to predict mortality.

Entities:  

Mesh:

Year:  2020        PMID: 32191764      PMCID: PMC7082074          DOI: 10.1371/journal.pone.0230548

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

In December, 2019, a series of pneumonia cases linked to a seafood and wet animal wholesale market emerged in Wuhan, Hubei, China [1]. Deep sequencing analysis from lower respiratory tract samples indicated a novel coronavirus, which was named 2019 novel coronavirus (2019-nCoV) [2]. By 4 Feb 2020 a total 24,324 cases have been confirmed infection nationwide with 3,219 severe cases, 490 death cases, and another 23,260 suspected cases [3]. Reports have also been released of exported cases in many other countries. WHO had determined this situation should be deemed a public health emergency of international concern on 30 Jan 2020 [4]. Symptoms of 2019-nCoV infected pneumonia (NCIP) include fever and/or respiratory illness, lymphopenia, and radiologic abnormality [5-7], among these clinical features, radiologic characteristics of NCIP are especially important for diagnosing and predicting prognosis. We herein summarize the clinical and radiologic characteristics of 27 confirmed cases and analyze the association of radiologic findings with mortality cases.

Methods

Patients

This retrospective study was approved by the Institutional Review Boards of Hubei Public Health Clinical Center, the central Hospital of Wuhan, and written informed consent was waived. Between 1 January 2020 and 25 January 2010, 27 consecutive patients who fulfilled the clinical criteria for 2019 novel coronavirus (2019-nCoV) infected pneumonia (NCIP) established by the WHO interim guidance [8] and discharged with recovered symptoms or died in hospital were included. Diagnosis of NCIP was made by positive test for 2019-nCoV viral RNA, in throat-swab specimens collected from patients by real-time reverse transcription polymerase chain reaction (RT-PCR) using standard RTPCR protocol at Hubei Provincial Center for Disease Control and Prevention (CDC). Clinical characteristics together with chest imaging manifestations of each confirmed cases were recorded, if available. All patients were treated with intravenous ribavirin 0.5g twice daily and/or oral oseltamivir 75 mg, twice daily. Antibiotics, including levofloxacin, moxifloxacin, sulbactam and cefoperazone, piperacillin and meropenem were used. Some patients also received glucocorticoid and/or intravenous immunoglobulin administration.

CT scans

The technical parameters included 64-section scanner with 1 mm collimation at 5 mm intervals. All CT examinations were performed with the patient in the supine position and with breath-holding following inspiration, without administration of contrast material. Images were obtained with both mediastinal (width 350 HU; level 40 HU) and parenchymal (width 1500 HU; level -600 HU) window settings.

Imaging evaluation

Two experienced pulmonologists (YML, YW) reviewed the images independently, with a final finding reached by consensus when there was a discrepancy. CT findings included ground glass opacity, consolidation, air bronchogram and nodular opacities. Ground glass opacity (GGO) was defined as hazy areas of increased opacity or attenuation without concealing the underlying vessels. Consolidation was defined as homogeneous opacification of the parenchyma obscuring the underlying vessels. Air bronchogram was defined as a pattern of air-filled (low-attenuation) bronchi on a background of opaque (high-attenuation) airless lung. Nodular opacities were defined as focal round opacities either solid nodules or GGOs (diameter ≤ 3 cm). The presence of lymphadenopathy was defined as a lymph node ≥ 1 cm in short-axis diameter. The CT scans were scored on the axial images referring to the method described previously [9]. The extent of involvement of each abnormality was assessed independently for each of 3 zones: upper (above the carina), middle (below the carina and above the inferior pulmonary vein), and lower (below the inferior pulmonary vein). The location of the lesion was defined as peripheral if it was in the outer one-third of the lung, or as central otherwise. The CT findings were graded on a 3-point scale: 1 as normal attenuation, 2 as ground-glass attenuation, and 3 as consolidation. Each lung zone, with a total of six lung zones in each patient, was assigned a following scale according to distribution of the affected lung parenchyma: 0 as normal, 1 as < 25% abnormality, 2 as 25–50% abnormality, 3 as 50–75% abnormality, and 4 as > 75% abnormality. The four-point scale of the lung parenchyma distribution was then multiplied by the radiologic scale described above. Points from all zones were added for a final total cumulative score, with value ranging from 0 to72 (Fig 1).
Fig 1

A sample scoring on CT images of a 63-year-old woman from mortality group demonstrated a total score of 63.

It was calculated as: for upper zone (A), 3 (consolidation) × 3 (50–75% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) ×1 (< 25% distribution) × 2 (both right and left lungs); for middle zone (B), 3 (consolidation) × 2 (25–50% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) × 2 (25–50% distribution) × 2 (both right and left lungs); for lower zone (C), 3 (consolidation) × (2 (25–50% distribution of the right lung) + 3 (50–75% distribution of the left lung)) + 2 (ground glass opacity) × (2 (25–50% distribution of the right lung) + 1 (< 25% distribution of the left lung)).

A sample scoring on CT images of a 63-year-old woman from mortality group demonstrated a total score of 63.

It was calculated as: for upper zone (A), 3 (consolidation) × 3 (50–75% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) ×1 (< 25% distribution) × 2 (both right and left lungs); for middle zone (B), 3 (consolidation) × 2 (25–50% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) × 2 (25–50% distribution) × 2 (both right and left lungs); for lower zone (C), 3 (consolidation) × (2 (25–50% distribution of the right lung) + 3 (50–75% distribution of the left lung)) + 2 (ground glass opacity) × (2 (25–50% distribution of the right lung) + 1 (< 25% distribution of the left lung)).

Statistical analysis

Continuous variables were expressed as median (interquartile range, IQR) and compared with the Mann-Whitney U test or Wilcoxon test; categorical variables were expressed as number (%) and compared by χ2 test or Fisher’s exact test if appropriate. A two-sided α of less than 0.05 was considered statistically significant. Statistical analyses were done using the SPSS (version 16.0).

Results

As shown in Table 1, the 27 patients diagnosed as 2019 novel coronavirus (2019-nCoV) infected pneumonia (NCIP) included 12 men and 15 women, with median age of 60 years (IQR 47–69). 17 patients discharged in recovered condition with twice negative test for 2019-nCoV viral RNA in throat-swab specimens and 10 patients died in hospital. The median age of mortality group was higher compared to survival group (68 (IQR 63–73) vs 55 (IQR 35–60), P = 0.003). The comorbidity rate in mortality group was significantly higher than in survival group (80% vs 29%, P = 0.018), especially comorbid hypertension, diabetes, and cardiac disease. 11 patients developed acute respiratory distress syndrome and required non-invasive ventilator mechanical ventilation, 10 of whom died, and one 36 years old man (oxygenation index: 184 mmHg) recovered after treatment. There were no significant differences between survival group and mortality group with respect to patient sex and symptoms.
Table 1

Demographics, comorbidities, and clinical presentations in mortality and survival groups.

VariableAll patientsN = 27Survival groupN = 17Mortality groupN = 10P value
Age, median(IQR), years60 (47–69)55 (35–60)68 (63–73)0.003
Male sex12 (45)8 (47)4 (40)1.000
Comorbidity13 (48)5 (29)8 (80)0.018
Hypertension5 (19)05 (50)0.003
Diabetes6 (22)06 (60)0.001
Cardiac disease3 (11)03 (30)0.041
Tumor1 (4)1 (6)01.000
Cerebral infarction1 (4)01 (10)0.370
Chronic gastritis1 (4)1 (6)01.000
ARDS11 (41)1 (6)10 (100)< 0.0001
Symptoms
 Fever21 (78)15 (88)6 (60)0.153
 Cough16 (59)11 (65)5 (50)0.687
 Myalgia3 (11)2 (12)1 (10)1.000
 Dyspnea11 (41)1 (6)10 (100)1.000

Percentages are in parentheses, unless indicated as median (interquartile range, IQR).

ARDS: acute respiratory distress syndrome.

Percentages are in parentheses, unless indicated as median (interquartile range, IQR). ARDS: acute respiratory distress syndrome. The CT features, including the location, extent and distribution of involvement of each abnormality were shown in Table 2. The median days of CT scans were 8 (IQR 5–11) before symptom onset in all patients. The predominant CT characteristics consisted of ground glass opacity (67%), bilateral sides involved (86%), both peripheral and central distribution (74%), and lower zone involved (96%). Lymphadenopathy and pleural effusion were relatively seldom seen (0% and 4%). The median CT score of mortality group was higher compared to survival group (30 (IQR 7–13) vs 12 (IQR 11–43), P = 0.021), with more frequency of consolidation (40% vs 6%, P = 0.047) and air bronchogram (60% vs 12%, P = 0.025) (Fig 2).
Table 2

CT features in mortality and survival groups.

CT featuresAll patientsN = 27Survival groupN = 17Mortality groupN = 10P Value
Symptom onset before CT, median (IQR), days8 (5–11)9 (5.5–10.5)7.5 (3–15)0.919
CT score, median (IQR)12 (8–29)12 (7–13)30 (11–43)0.021
GGO18 (67)12 (71)6 (60)0.683
Consolidation5 (19)1 (6)4 (40)0.047
both8 (30)4 (24)4 (40)0.415
Air bronchogram8 (30)2 (12)6 (60)0.025
Nodular opacities2 (7)2 (12)00.516
Lymphadenopathy000
Pleural effusions1 (4)1 (6)01.000
 Unilateral000
 Bilateral1 (4)1 (6)01.000
Anatomic sides involved
 Unilateral4 (15)4 (24)00.264
 Bilateral23 (86)13 (76)10 (100)0.264
Predominant distribution
 Central000
 Peripheral7 (26)6 (35)1 (10)0.204
 Both20 (74)11 (65)9 (90)0.204
Involved zone
 Upper22 (81)14 (82)8 (80)1.000
 Middle23 (85)15 (88)9 (90)1.000
 Lower26 (96)16 (94)10 (100)1.000

Percentages are in parentheses, unless indicated as median (interquartile range, IQR).

GGO: ground glass opacity.

Fig 2

Comparison of CT images between survival group and mortality group.

CT images of a 76-year-old woman from survival group showed pure ground glass opacities with predominant peripheral distribution in middle and lower lung zones (A-C). Air bronchogram, together with extensive of consolidations and ground glass opacities were found in the CT images of a 72–year-old woman from mortality group (D-F).

Comparison of CT images between survival group and mortality group.

CT images of a 76-year-old woman from survival group showed pure ground glass opacities with predominant peripheral distribution in middle and lower lung zones (A-C). Air bronchogram, together with extensive of consolidations and ground glass opacities were found in the CT images of a 72–year-old woman from mortality group (D-F). Percentages are in parentheses, unless indicated as median (interquartile range, IQR). GGO: ground glass opacity. In the receiver operating characteristic curve analysis (Fig 3), an optimal cutoff value of a CT score of 24.5 had a sensitivity of 85.6% and a specificity of 84.5% for the prediction of mortality. The area under the receiver operating characteristic curve was 0.901 (95% confidence interval: 0.873, 0.928).
Fig 3

ROC analysis of the CT score for prediction of mortality.

N = 27; AUC = 0.901.

ROC analysis of the CT score for prediction of mortality.

N = 27; AUC = 0.901. Initial and reexamined CT features on day 15 (IQR 9–18) after symptom onset in survival group were compared in 11 patients. As shown in Fig 4, some cases exhibited a certain degree of progression, however the morphology of the lesions, the location, extent and distribution of involvement of each abnormality were not significantly changed compared to those on admission (Table 3). In mortality group, CT scores progressed rapidly in a short time (12 (IQR 5–24.5) vs 20 (IQR 15–46), P = 0.042), with more lung zones being involved (Table 4).
Fig 4

Two cases of CT images from survival group showed ground glass nodular opacities on admission and progressed to multiple patchy ground glass opacities on reexamination.

The CT images of a 60-year-old woman on admission showed peripherally distributed focal ground glass nodular opacities in only right lung (A) and rechecked CT images showed expanded area of patchy ground glass opacities in both right and left lungs with reticular and interlobular septal thickening on 7 days later (B). Unilateral ground glass nodular opacity was found on CT images of a 64-year-old man from survival group (C) and progressed patchy ground glass opacities as well as interlobular septal thickening were seen after 4 days (D).

Table 3

Comparison of CT features in survival group between admission and reexamination.

CT featuresAdmissionN = 11ReexaminationN = 11P Value
Symptom onset before CT, median (IQR), days7 (5–10)15 (9–18)
CT score, median (IQR)12 (6–12)12 (6–15)0.237
GGO8 (73)7(64)1.000
Consolidation1(9)01.000
both2(18)4 (36)0.635
Air bronchogram1(9)01.000
Nodular opacities2 (18)1 (9)1.000
Lymphadenopathy00
Pleural effusions01 (9)1.000
Unilateral00
Bilateral01 (9)1.000
Anatomic sides involved
 Unilateral3 (27)2 (18)1.000
 Bilateral8(73)9 (82)1.000
Predominant distribution
 Central00
 Peripheral5 (45)4 (36)1.000
 Both6 (55)7(64)1.000
Involved zone
 Upper7(64)7(64)1.000
 Middle8(73)11 (100)0.214
 Lower10(91)10 (91)1.000

Percentages are in parentheses, unless indicated as median (interquartile range, IQR).

GGO: ground glass opacity.

Table 4

Comparison of CT features in mortality group between admission and reexamination.

CT featuresAdmissionN = 5ReexaminationN = 5P Value
Symptom onset before CT, median (IQR), days8 (2–22.5)11 (4.5–27.5)
CT score, median (IQR)12 (5–24.5)20 (15–46)0.042
GGO4 (80)4 (80)1.000
Consolidation00
both1 (20)1 (20)1.000
Air bronchogram1 (20)1 (20)1.000
Nodular opacities00
Lymphadenopathy00
Pleural effusions00
Unilateral00
Bilateral00
Anatomic sides involved
 Unilateral00
 Bilateral5 (100)5 (100)1.000
Predominant distribution
 Central00
 Peripheral1 (20)01.000
 Both4 (80)5 (100)1.000
Involved zone
 Upper3 (60)5 (100)0.444
 Middle4 (80)5 (100)1.000
 Lower5 (100)5 (100)1.000

Percentages are in parentheses, unless indicated as median (interquartile range, IQR).

GGO: ground glass opacity.

Two cases of CT images from survival group showed ground glass nodular opacities on admission and progressed to multiple patchy ground glass opacities on reexamination.

The CT images of a 60-year-old woman on admission showed peripherally distributed focal ground glass nodular opacities in only right lung (A) and rechecked CT images showed expanded area of patchy ground glass opacities in both right and left lungs with reticular and interlobular septal thickening on 7 days later (B). Unilateral ground glass nodular opacity was found on CT images of a 64-year-old man from survival group (C) and progressed patchy ground glass opacities as well as interlobular septal thickening were seen after 4 days (D). Percentages are in parentheses, unless indicated as median (interquartile range, IQR). GGO: ground glass opacity. Percentages are in parentheses, unless indicated as median (interquartile range, IQR). GGO: ground glass opacity.

Discussion

Coronaviruses (CoV) are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) emerged in 2012 and Severe Acute Respiratory Syndrome (SARS-CoV) emerged in 2002. A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans [10]. The 2019-nCoV causes symptoms similar to SARS based on recent clinical data [5, 6], and is capable of spreading from human to human and between cities, with very contagious characteristic [11]. The basic reproductive number was estimated to be 2.2 [12]. The mortality of the 27 included patients infected by 2019-nCoV was 37%, which is much higher than that reported 2% on 4 Feb 2020 [3]. Giving the priority of 2019-nCoV detection to severe cases because of shortness of test kits in our hospital initially and potential false negative results of 2019-nCoV viral RNA detection in mild cases might account for this discrepancy. Consistent with recent reports, our results suggest that 2019-nCoV is more likely to infect elderly people with chronic comorbidities as a result of the weaker immune functions of these patients [5, 6], and 2019-nCoV-associated death is also related to elder age and underlying illnesses, especially hypertension, diabetes, and cardiac disease. Consistently with several recent reports regarding to CT findings of 2019-nCoV infected pneumonia (NCIP) [13-15], our results showed that CT manifestations of NCIP were featured by predominant ground glass opacities (GGO) (67%) mixed with consolidations (30%), mainly peripheral (26%) or combined peripheral and central distributions (74%), bilateral (86%) and lower lung zones (96%) being mostly involved. Merely consolidation, central distribution only, pleural effusions or lymphadenopathy were relatively rarely seen. Initially the CT images might be GGO nodules or patchy GGO mostly peripherally distributed then consolidations and extensive distributions were seen when pneumonia progressed. Consolidation, air bronchogram, extensive distribution as well as multiple involved lung zones were more common in mortality group, suggesting a more severe clinical course for these abnormalities can be pathologically correlated with diffuse alveolar damage and similar conclusions can be drawn in H1N1 pneumonia, H5N1 pneumonia, H7N9 pneumonia and SARS [9, 16–18]. As members of the same virus family, NCIP shared much common ground with MERS and SARS in CT features. Subpleural and basilar airspace lesions with GGOs and consolidations were conspicuous CT characteristics of all three kinds of virus pneumonia, but pleural effusions are more common in patients who died of MERS [19-22]. Comprehensively evaluated the CT features of NCIP, we calculated the CT score of each patient. The CT scores were much higher in mortality group compared to survival group (30 (IQR 7–13) vs 12 (IQR 11–43), 0.021), P = 0.021) on admission. In mortality group the scores markedly increased in a short time (12 (IQR 5–24.5) vs 20 (IQR 15–46), P = 0.042), suggesting a progressive course of NCIP. Although the CT scores were not diminished, they maintained a relatively stable level for a period of time in survival group (12 (IQR 6–12) vs 12 (IQR 6–15), P = 0.237), suggesting that it might take a long time to recover in chest imaging when NCIP was under controlled. We found an optimal cutoff value of a CT score of 24.5 (sensitivity of 85.6% and specificity of 84.5%) to predict mortality. We hope the simple scoring method according to CT scans may help triage patients and screening patients who need more aggressive treatment and closely monitoring. However, the efficacy of such approach to decrease mortality remains to be validated in future studies. Although a definite diagnosis of NCIP cannot be achieved by using imaging features alone for most viral pneumonia imaging patterns share similarity, the CT features summarized above might be helpful in differentiation various pathogens of pneumonia and in triage patients. There were limitations in our study. First it was a retrospective study including only 27 inpatients, while outpatients and suspected but undiagnosed cases for deficiency of detection kits of 2019-nCoV and potential false negative results were ruled out. Second, not all information was collected because a significant part of patients had not rechecked CT scans. Then, it was pulmonologists, although they are experienced, who evaluated CT images. Finally there was a lack of information regarding interobserver agreement, because the study emphasis on the final consensus interpretation rather than independent reading.
  17 in total

1.  Influenza A (H1N1) virus-associated pneumonia: high-resolution computed tomography-pathologic correlation.

Authors:  Edson Marchiori; Gláucia Zanetti; Cristina Asvolinsque Pantaleão Fontes; Maria Lúcia Oliveira Santos; Paulo Marcos Valiante; Cláudia Mauro Mano; Graça Helena Canto Teixeira; Bruno Hochhegger
Journal:  Eur J Radiol       Date:  2010-10-30       Impact factor: 3.528

2.  Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings.

Authors:  Amr M Ajlan; Rayan A Ahyad; Lamia Ghazi Jamjoom; Ahmed Alharthy; Tariq A Madani
Journal:  AJR Am J Roentgenol       Date:  2014-06-11       Impact factor: 3.959

3.  Emerging H7N9 influenza A (novel reassortant avian-origin) pneumonia: radiologic findings.

Authors:  Qingle Wang; Zhiyong Zhang; Yuxin Shi; Yebin Jiang
Journal:  Radiology       Date:  2013-07-02       Impact factor: 11.105

Review 4.  Coronaviruses: severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus in travelers.

Authors:  Jaffar A Al-Tawfiq; Alimuddin Zumla; Ziad A Memish
Journal:  Curr Opin Infect Dis       Date:  2014-10       Impact factor: 4.915

5.  Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients.

Authors:  K T Wong; Gregory E Antonio; David S C Hui; Nelson Lee; Edmund H Y Yuen; Alan Wu; C B Leung; T H Rainer; Peter Cameron; Sydney S C Chung; Joseph J Y Sung; Anil T Ahuja
Journal:  Radiology       Date:  2003-05-20       Impact factor: 11.105

6.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

7.  Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China.

Authors:  Weier Wang; Jianming Tang; Fangqiang Wei
Journal:  J Med Virol       Date:  2020-02-12       Impact factor: 2.327

8.  CT Manifestations of Two Cases of 2019 Novel Coronavirus (2019-nCoV) Pneumonia.

Authors:  Yicheng Fang; Huangqi Zhang; Yunyu Xu; Jicheng Xie; Peipei Pang; Wenbin Ji
Journal:  Radiology       Date:  2020-02-07       Impact factor: 11.105

9.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

Authors:  Qun Li; Xuhua Guan; Peng Wu; Xiaoye Wang; Lei Zhou; Yeqing Tong; Ruiqi Ren; Kathy S M Leung; Eric H Y Lau; Jessica Y Wong; Xuesen Xing; Nijuan Xiang; Yang Wu; Chao Li; Qi Chen; Dan Li; Tian Liu; Jing Zhao; Man Liu; Wenxiao Tu; Chuding Chen; Lianmei Jin; Rui Yang; Qi Wang; Suhua Zhou; Rui Wang; Hui Liu; Yinbo Luo; Yuan Liu; Ge Shao; Huan Li; Zhongfa Tao; Yang Yang; Zhiqiang Deng; Boxi Liu; Zhitao Ma; Yanping Zhang; Guoqing Shi; Tommy T Y Lam; Joseph T Wu; George F Gao; Benjamin J Cowling; Bo Yang; Gabriel M Leung; Zijian Feng
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 176.079

Review 10.  MERS, SARS and other coronaviruses as causes of pneumonia.

Authors:  Yudong Yin; Richard G Wunderink
Journal:  Respirology       Date:  2017-10-20       Impact factor: 6.424

View more
  173 in total

Review 1.  Radiological approach to COVID-19 pneumonia with an emphasis on chest CT.

Authors:  Serkan Güneyli; Zeynep Atçeken; Hakan Doğan; Emre Altınmakas; Kayhan Çetin Atasoy
Journal:  Diagn Interv Radiol       Date:  2020-07       Impact factor: 2.630

2.  Prevalence and impact of diabetes in patients with COVID-19 in China.

Authors:  Min Du; Yu-Xin Lin; Wen-Xin Yan; Li-Yuan Tao; Min Liu; Jue Liu
Journal:  World J Diabetes       Date:  2020-10-15

Review 3.  A systematic review of chest imaging findings in COVID-19.

Authors:  Zhonghua Sun; Nan Zhang; Yu Li; Xunhua Xu
Journal:  Quant Imaging Med Surg       Date:  2020-05

4.  Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.

Authors:  Mohamad Hesam Shahrajabian; Wenli Sun; Qi Cheng
Journal:  Hum Vaccin Immunother       Date:  2020-08-12       Impact factor: 3.452

5.  Ultra-low-dose chest CT performance for the detection of viral pneumonia patterns during the COVID-19 outbreak period: a monocentric experience.

Authors:  Joël Greffier; Adel Hoballah; Alexandre Sadate; Fabien de Oliveira; Pierre-Geraud Claret; Hélène de Forges; Paul Loubet; Jean-Marc Mauboussin; Aymeric Hamard; Jean-Paul Beregi; Julien Frandon
Journal:  Quant Imaging Med Surg       Date:  2021-07

6.  Clinical course and risk factors of fatal adverse outcomes in COVID-19 patients in Korea: a nationwide retrospective cohort study.

Authors:  Juhyun Song; Dae Won Park; Jae-Hyung Cha; Hyeri Seok; Joo Yeong Kim; Jonghak Park; Hanjin Cho
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

Review 7.  Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents.

Authors:  Giorgio Costagliola; Erika Spada; Rita Consolini
Journal:  Pediatr Rheumatol Online J       Date:  2021-05-04       Impact factor: 3.054

8.  Quantitative evaluation of COVID-19 pneumonia severity by CT pneumonia analysis algorithm using deep learning technology and blood test results.

Authors:  Tomohisa Okuma; Shinichi Hamamoto; Tetsunori Maebayashi; Akishige Taniguchi; Kyoko Hirakawa; Shu Matsushita; Kazuki Matsushita; Katsuko Murata; Takao Manabe; Yukio Miki
Journal:  Jpn J Radiol       Date:  2021-05-14       Impact factor: 2.374

9.  Thoracic imaging tests for the diagnosis of COVID-19.

Authors:  Nayaar Islam; Sanam Ebrahimzadeh; Jean-Paul Salameh; Sakib Kazi; Nicholas Fabiano; Lee Treanor; Marissa Absi; Zachary Hallgrimson; Mariska Mg Leeflang; Lotty Hooft; Christian B van der Pol; Ross Prager; Samanjit S Hare; Carole Dennie; René Spijker; Jonathan J Deeks; Jacqueline Dinnes; Kevin Jenniskens; Daniël A Korevaar; Jérémie F Cohen; Ann Van den Bruel; Yemisi Takwoingi; Janneke van de Wijgert; Johanna Aag Damen; Junfeng Wang; Matthew Df McInnes
Journal:  Cochrane Database Syst Rev       Date:  2021-03-16

10.  Automated AI-Driven CT Quantification of Lung Disease Predicts Adverse Outcomes in Patients Hospitalized for COVID-19 Pneumonia.

Authors:  Marie Laure Chabi; Ophélie Dana; Titouan Kennel; Alexia Gence-Breney; Hélène Salvator; Marie Christine Ballester; Marc Vasse; Anne Laure Brun; François Mellot; Philippe A Grenier
Journal:  Diagnostics (Basel)       Date:  2021-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.